

# VISIBILITY AND MARKET RECOGNITION FOR A BIOPHARMA COMPANY



## Fundraising announcement



After raising €65M (\$71M) for its Series A financing round, Corteria Pharmaceuticals, a biopharmaceutical company developing first-in-class drugs in heart failure subpopulations, wished to increase its visibility and gain market recognition.

### **Objectives**:


- To use the funding news to gain brand recognition and increase visibility in national, international and specialized media
- To present the company's corporate and scientific developments to the international life sciences and investment ecosystem

#### Strategy:

- Conducted embargoed interviews to prepare news distribution
- Wrote and issued news announcement in French and English
- Liaised with key publications to organize interviews and generate coverage in top-tier media

#### **Results:**

- The announcements generating 48 articles, with coverage in leading French and international publications, including Les Echos, Biotech Finances, BFM Business, Endpoints News, Scrip, Fierce Biotech, BioWorld, **BioCentury, Sifted and The Wall Street Journal**
- Arranged **7** media briefings
- Audience of **109M** reached from the media coverage
- Positive reception on ALA social media accounts with 5.08% engagement rate on LinkedIn



"We have been pleased with ALA's support that helped us craft the right messages and have a strong outreach to specialized and financial media."

#### Philip Janiak, CEO of Corteria Pharmaceuticals